OverviewSuggest Edit

MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

TypePublic
Founded2000
HQSan Diego, CA, US
Websitemeipharma.com

Latest Updates

Employees (est.) (Jun 2019)40(+25%)
Job Openings7
Revenue (FY, 2020)$28.9 M(+489%)
Share Price (Apr 2021)$3.5(+2%)
Cybersecurity ratingAMore

Key People/Management at MEI Pharma

Daniel Gold

Daniel Gold

President & Chief Executive Officer
Christine A. White

Christine A. White

Non-Executive Chairman
Robert Mass

Robert Mass

Chief Medical Officer
Charles V. Baltic

Charles V. Baltic

Non-Executive Director
Brian Drazba

Brian Drazba

Chief Financial Officer
Kevan Clemens

Kevan Clemens

Non-Executive Director
Show more

MEI Pharma Office Locations

MEI Pharma has an office in San Diego
San Diego, CA, US (HQ)
3611 Valley Centre Dr #500
San Diego, CA, US
11455 El Camino Real #250
Show all (2)

MEI Pharma Financials and Metrics

MEI Pharma Revenue

MEI Pharma's revenue was reported to be $28.91 m in FY, 2020
USD

Revenue (Q2, 2021)

9.2m

Gross profit (Q2, 2021)

8.7m

Gross profit margin (Q2, 2021), %

94.6%

Net income (Q2, 2021)

(11.5m)

EBIT (Q2, 2021)

(19.2m)

Market capitalization (23-Apr-2021)

384.8m

Closing stock price (23-Apr-2021)

3.5

Cash (31-Dec-2020)

9.9m

EV

383.6m
MEI Pharma's current market capitalization is $384.8 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

23.2m1.6m4.9m28.9m

Cost of goods sold

5.0m3.4m4.3m2.7m

Gross profit

18.2m(1.8m)652.0k26.2m

Gross profit Margin, %

78%(109%)13%91%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Revenue

1.1m17.2m4.5m283.0k358.0k433.0k488.0k2.0m1.2m1.2m1.0m1.2m9.2m

Cost of goods sold

1.1m1.8m1.1m618.0k728.0k930.0k989.0k1.0m1.2m688.0k641.0k860.0k494.0k

Gross profit

2.0k15.4m3.4m(335.0k)(370.0k)(497.0k)(501.0k)1.0m86.0k469.0k367.0k384.0k8.7m

Gross profit Margin, %

0%90%75%(118%)(103%)(115%)(103%)51%7%41%36%31%95%
USDQ1, 2012

Financial Leverage

1.5 x
Show all financial metrics

MEI Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

MEI Pharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

MEI Pharma Online and Social Media Presence

Embed Graph

MEI Pharma Company Culture

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

MEI Pharma News and Updates

MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA)

SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new...

MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers

SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that...

MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase ("PI3K")...

SHAREHOLDER ALERT FILING DEADLINE: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – MEIP

NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc. (“MEI” or the “Company”) (NASDAQ: MEIP) and certain of its officers.   The class action, filed in United States District Court for the Southern District of Califo…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – MEIP

NEW YORK, Sept. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc. (“MEI” or the “Company”) (NASDAQ: MEIP) and certain of its officers.   The class action, filed in United States District Court for the Southern District of Calif…

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of Important October 9 Deadline in Securities Class Action – MEIP

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (the “Class Period”), of the important October 9, 2020 lead plaintiff deadline …
Show more

MEI Pharma Frequently Asked Questions

  • When was MEI Pharma founded?

    MEI Pharma was founded in 2000.

  • Who are MEI Pharma key executives?

    MEI Pharma's key executives are Daniel Gold, Christine A. White and Robert Mass.

  • How many employees does MEI Pharma have?

    MEI Pharma has 40 employees.

  • What is MEI Pharma revenue?

    Latest MEI Pharma annual revenue is $28.9 m.

  • What is MEI Pharma revenue per employee?

    Latest MEI Pharma revenue per employee is $722.8 k.

  • Who are MEI Pharma competitors?

    Competitors of MEI Pharma include ESSA Pharma, Celltrion Healthcare and Kyowa Kirin.

  • Where is MEI Pharma headquarters?

    MEI Pharma headquarters is located at 3611 Valley Centre Dr #500, San Diego.

  • Where are MEI Pharma offices?

    MEI Pharma has an office in San Diego.

  • How many offices does MEI Pharma have?

    MEI Pharma has 2 offices.